15-Deoxyspergualin: A newly developed immunosuppressive agent and its mechanism of action and clinical effect: A review

Artificial Organs

Volumn 20, Issue 8, 1996, Pages 832-835

  Amemiya, Hiroshi ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

15 Deoxyspergualin; Clinical trial; Immunosuppressive agent

Indexed keywords

MEDICAL APPLICATIONS;

15-DEOXYSPERGUALIN; ACTION EFFECT; ACUTE REJECTION; CLINICAL EFFECTS; CLINICAL TRIAL; CULTURE FILTRATE; IMMUNOSUPPRESSIVE AGENT; IMMUNOSUPPRESSIVE EFFECTS; MECHANISM OF ACTION; SYNTHETIC ANALOGUES;

BACTERIOLOGY;

15 DEOXYSPERGUALIN; METHYLPREDNISOLONE;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; GRAFT REJECTION; HEART; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RAT; SURVIVAL;

ANIMALIA; BREVIBACILLUS LATEROSPORUS; CANIS FAMILIARIS;

EID: 0029786784     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04555.x     Document Type: Article

References (21)

1. Umezawa H, Kondo S, Iinuma H, Kunimoto S, Ikeda Y, Iwusuwa H, Ikeda D, Takeuchi T. Structure of un antitumor antibiotic spergualin. J Antibiot 1981;34:1622-4.
2. Fujii H, Takeda T, Nemoto K, Abe F, Fujii A, Talmadge JE, Takeuchi T. Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. Int J Immunopharm 1992;14:731-7.
3. Hiratsuka M, Kuramochi H, Takahashi K. Cytostatic effect of deoxyspergualin on a murine leukemia cell line L 1210. Jpn J Cancer Res 1991;82:1065-8.
4. Amemiya H. 15-Deoxyspergualin. In: Kupiec-Weglinski JW. ed. New immunosuppressive modalities and antirejection approaches in organ transplantation. Boston, MA: Landes Company/Austin; 1994, 75-91.
5. Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp 70 family of heat shock proteins. Science 1992;258:484-6.
6. Nemoto K, Abe F, Nakamtira T, Ishizuka M, Takeuchi T, Umezawa H. Blastogenic responses and the release of interleukins 1 and 2 by spleen cells obtained from rat skin allograft recipients administered with 15-deoxyspergualin. J Antibiot 1987;40:1062-4.
7. Fujii H, Takada T, Nemoto K, Abe F, Fujii A, Takeuchi T. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot 1989;42:788-94.
8. Nishimura K, Tokunaga T. Mechanism of action of 15-deoxyspergualin. 1. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. Immunology 1989;68:66-71.
9. Fujii H, Takada T, Nemoto K, Yamashita T, Abe F, Fujii A, Takeuchi T. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 1990:43:213-9.
10. Suzuki S, Kanashiro M, Watanabe H, Amemiya H. Therapeutic effect of 15-deoxyspergualin on acute graft rejection detected by 31P nuclear magnetic resonance spectrography, and its effect on rat heart transplantation. Transplantation 1988;46:669-72.
11. Amemiya H, Suzuki S, Manabe H, Fukao K, Iwasaki Y, Dohi K, Isono K, Orita K, Yamanaka N. 15-deoxyspergualin as an immunosuppressive agent in dogs. Transplant Proc 1988;20:229-32.
12. Niiya S, Suzuki S, Hayashi R, Watanabe H, Ito J, Amemiya H. 15-deoxyspergualin: A powerful rescue drug for rejection in canine kidney grafting. Transplant Proc 1989;21:1076.
13. Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Omoto R, Koyama I, Dohi K, Fukuda Y, Fukao K, Ishibashi M. Early phase II study of deoxyspergualin (NKT-01) for renal allograft rejection. J Jpn Soc Transplant 1991 ;26:604-14 (English summary).
14. Amemiya H, Ota K, Sonoda T, Fukao K, Taguchi Y, Isono K, Omoto R, Takagi H. Oka T, Orita K, Dohi K. Dose finding study of deoxyspergualin (NKT-01) for renal allograft rejection. J Jpn SocTransplant 1991:26:615-28 (English summary).
15. Amemiya H, Taguchi Y, Fukao K, Isono K, Omolo R, Ota K, Kozaki M, Takagi H, Oka T, Sonoda T, Orita K, Dohi K. Late phase II study of NKT-01 for renal allograft rejection. Clin Report 1991;25:3491-500 (Japanese).
16. Amemiya H, Taguchi Y, Fukao K, Isono K, Omoto R, Ota K, Kozaki M,Takagi H, Oka T, Sonoda T, Orita K, Dohi K. Clinical study of NKT-01 for refractory renal allograft rejection. Clin Report 1991;25:3501-8 (Japanese).
17. Amemiya H, Dohi K, Otsubo O, Endo T, Nagano S, Ishibashi M, Hirano T, Sato K, Kurita T. Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methylprednisolone in kidney recipient. Transplant Proc 1991;23:1087-9.
18. Takahashi K, Tanabe K, Ooba S, Yagisawa T, Nakazawa H, Teraoka S, Hayasaka Y, Kawaguchi H, Ito K, Toma H, Fugii K, Shimizu M, Agishi T, Ota K. Prophylactic use of a new immunosuppressive agent, deoxyspergualin, in patients with kidney transplantation from ABO-incompatible or preformed antibody-positive donors. Transplant Proc 1991;23: 1078-82.
19. Suzuki S, Nishimori H, Kido K, Arita S, Tashiro H, Ohdan H, Quinones D, Amemiya H. Continuous administration of methyldeoxyspergualin prolongs xenograft survival in hamster-to-rat cardiac transplantation. Transplant Proc 1993;25:430-1.
20. Suzuki S. Deoxyspergualin: Mode of action and effects on graft rejection. In: Thomson AW, Starzl TE, eds. Immunosuppressive drugs: Developments in anti-rejection therapy. London: Edward Arnold, 1994;187-202.
21. Groth CG, Ohlman S, Ericzon BC, Barkholt L, Reinholt FP. Deoxyspergualin for liver graft rejection. Lancet 1990;336:626.